A look at how the Apple Watch is poised to disrupt the highly regulated healthcare industry and what diagnostics and screening apps Apple may add in the future
I don't own an Apple Watch. I do have a Fitbit. But the Apple Watch 4 announcement intrigued me in a way no other product has since the original IPhone.
Context & Ripple Effects
This piece sits at the start of a long arc: back in 2015 the FDA signaled it was taking a very light touch to regulating the Apple Watch, which cleared the runway for Apple to ship health features without treating the watch like a Class II medical device. The Watch 4 announcement is the moment that posture starts to matter — sensors good enough to screen for conditions turn a fitness accessory into a front-door diagnostic.
The follow-on coverage shows why the disruption thesis was slow to cash out: by early 2022, experts told the Financial Times the watch had yet to change patient management, with Apple struggling to win FDA approvals and broader doctor acceptance. Yet by mid-2024 the Wall Street Journal found doctors using the Apple Watch to diagnose and manage patient conditions anyway — adoption happening around the formal pathway rather than through it.
First-order effects
- Apple's push into diagnostics immediately puts screening data in consumers' hands before clinicians see it, forcing doctors to interpret watch-generated readings alongside — or instead of — their own FDA-approved equipment.
- Every new capability Apple adds (the blood pressure sensor and paid health service Bloomberg reported for the 2024 watch) has to clear the same regulatory gate the 2015 light-touch era let it skip.
Second-order effects
- Medical-device makers whose products target the same screenings face competition from a device consumers already wear daily, shifting the battleground from clinical accuracy alone to continuous, zero-effort data capture.
- Payers and health systems gain a new input stream they didn't ask for: if doctors are acting on watch data regardless of formal approval, liability and reimbursement questions land on them whether or not Apple intended it.
Third-order effects
- If the pattern holds — consumer hardware iterating faster than FDA clearance cycles — healthcare's screening layer migrates to the wrist first and the clinic second, with regulators forced to formalize rules for consumer-grade diagnostics after adoption rather than before.
- A paid Apple health service layered on top would make Apple not just a sensor vendor but a care-adjacent platform, the same hardware-plus-subscription structure it used to build the iPhone ecosystem.
The trend: Consumer wearables are evolving from fitness trackers into regulated diagnostic platforms, with the pace of FDA clearance — not sensor capability — setting how fast the clinic follows the wrist.